Key result
Endogenous methylarginines, specifically L-NMMA and ADMA, accumulate in various diseases and act as endogenous inhibitors of nitric oxide synthase, contributing to impaired nitric oxide production.
Design
Review
Authors
Loading...
Should not yet alter clinical practice; leaves open therapeutic targeting of methylarginines in endothelial dysfunction.
Endogenous methylarginines such as ADMA and L-NMMA act as critical inhibitors of nitric oxide synthase, and their accumulation plays a key pathophysiological role in endothelial dysfunction and cardiovascular diseases.
Masuda et al. (2002) conducted a review in Diseases associated with impaired nitric oxide production. Endogenous methylarginines (L-NMMA, ADMA) was evaluated. Endogenous methylarginines, specifically L-NMMA and ADMA, accumulate in various diseases and act as endogenous inhibitors of nitric oxide synthase, contributing to impaired nitric oxide production.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: